SCHEMBL5284612

SCHEMBL5284612

O=[N+]([O-])c1ccc(Oc2ccc(NS(=O)(=O)c3cccc4nonc34)cc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.61
PKM P14618 1/20 0.55
MAPT P10636 3/20 0.54
MAPK1 P28482 3/20 0.54
MEN1 O00255 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
LMNA P02545 2/20 0.54
ALDH1A1 P00352 5/20 0.50
HSPD1 P10809 1/20 0.50
PTPN2 P17706 1/20 0.50
PTPN1 P18031 1/20 0.50
PTPN5 P54829 1/20 0.50
HSPE1 P61604 1/20 0.50
PGR P06401 2/20 0.49
POLB P06746 2/20 0.48
GFER P55789 1/20 0.48
GAA P10253 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
TP53 P04637 1/20 0.46
HTT P42858 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5242843 0.93 KMT2A (0.69) KMT2APKMMAPTMAPK1MEN1
SCHEMBL5243266 0.86 KMT2A (0.69) KMT2AMAPTMAPK1MEN1SMN1; SMN2
SCHEMBL5281337 0.84 KMT2A (0.66) KMT2AMAPTMEN1SMN1; SMN2LMNA
SCHEMBL5244667 0.80 KMT2A (0.70) KMT2AMAPTMAPK1MEN1SMN1; SMN2
SCHEMBL14433271 0.77 KMT2A (0.66) KMT2AMAPTMAPK1MEN1SMN1; SMN2
SCHEMBL14433266 0.76 KMT2A (0.76) KMT2AMAPTMAPK1MEN1SMN1; SMN2
SCHEMBL5242915 0.76 KMT2A (0.72) KMT2AMAPTMAPK1MEN1SMN1; SMN2
SCHEMBL5247001 0.75 KMT2A (0.73) KMT2AMAPTMAPK1MEN1SMN1; SMN2
SCHEMBL1472205 0.74 MEN1 (0.57) KMT2APKMMAPTMAPK1MEN1
SCHEMBL5290647 0.73 KMT2A (0.53) KMT2AMAPTMAPK1MEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1758873-A1 UBIQUITIN LIGASE INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2007-03-07 EP claimed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 WO claimed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 US claimed
WO-2008115259-A2 DERIVATIVES OF BENZOXADIAZOLE SUITABLE FOR THE TREATMENT OF CELL PROLIFERATIVE DISEASES RIGEL PHARMACEUTICALS, INC. (US) 2008-09-25 WO disclosed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 WO disclosed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282818-A1 Ubiquitin ligase inhibitors NEDD4, TRAF6, XIAP KMT2A 1303/4885PKM 4014/4885MAPT 1681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.